Aplastic anemia Medical Services in China

Aplastic anemia (AA) is a rare, life-threatening hematologic disorder characterized by bone marrow failure, resulting in pancytopenia—profound deficiencies of red blood cells, white blood cells, and platelets. Unlike leukemias or myelodysplastic syndromes, AA involves immune-mediated destruction or functional suppression of hematopoietic stem and progenitor cells, leading to hypocellular or acellular bone marrow without abnormal cell infiltration or fibrosis. The primary pathogenesis centers on autoreactive T-lymphocyte activation, which targets hematopoietic stem cells via cytokine-mediated apoptosis (e.g., IFN-γ and TNF-α overexpression) and Fas/FasL pathway dysregulation. In ~75% of cases, the disease is acquired, often triggered by environmental exposures—including benzene, certain medications (e.g., chloramphenicol, sulfonamides, anticonvulsants), viral infections (e.g., hepatitis viruses, Epstein-Barr virus, parvovirus B19), or idiopathic immune dysregulation. A smaller subset (<10%) arises from inherited bone marrow failure syndromes such as Fanconi anemia, Dyskeratosis congenita, or Shwachman-Diamond syndrome, typically presenting in childhood with associated physical anomalies and cancer predisposition. Epidemiologically, AA affects approximately 2–7 new cases per million people annually worldwide, with a bimodal age distribution peaking in adolescence/early adulthood (15–25 years) and again after age 60. Incidence is notably higher in East Asia, particularly China, where rates reach up to 10–15 per million—potentially reflecting genetic susceptibility, environmental factors, or enhanced case detection. Risk factors include occupational solvent exposure, prior chemotherapy or radiation, autoimmune disorders (e.g., lupus, thyroiditis), and specific HLA haplotypes (e.g., HLA-DR2). Clinically, patients present with fatigue, pallor, dyspnea (anemia), recurrent febrile infections (neutropenia), and mucocutaneous bleeding or petechiae (thrombocytopenia). Severe AA carries high mortality without treatment: median survival is <6 months untreated, with hemorrhage and sepsis being leading causes of death. Quality of life is significantly impaired—not only due to physical symptoms but also psychological burden, treatment-related side effects (e.g., immunosuppressive therapy-induced fatigue, infection risk, or GVHD post-transplant), prolonged hospitalizations, and socioeconomic strain from lost workdays and caregiving demands. Patients often experience anxiety, depression, and social isolation, especially during prolonged recovery phases or while awaiting matched donors for hematopoietic stem cell transplantation (HSCT). Early diagnosis via peripheral blood counts, reticulocyte count, and confirmatory bone marrow biopsy (showing <25% cellularity with absence of dysplasia or infiltrative disease) is critical. Prognosis depends on disease severity (classified as non-severe, severe, or very severe AA), age, comorbidities, and treatment response. With modern therapies—including immunosuppressive therapy (IST) with antithymocyte globulin [ATG] and cyclosporine, or allogeneic HSCT—5-year overall survival exceeds 80% in younger patients receiving matched sibling donor transplants and 70–75% with IST. However, relapse, clonal evolution (to MDS or AML), and chronic complications remain key challenges requiring lifelong monitoring.

Aplastic anemia (AA) is a rare, life-threatening bone marrow failure disorder characterized by pancytopenia—profound deficiency of red blood cells, white blood cells, and platelets—due to hypocellular or aplastic bone marrow with absent or markedly reduced hematopoietic stem and progenitor cells. The pathogenesis involves immune-mediated destruction of hematopoietic stem cells, often triggered by environmental exposures (e.g., benzene, certain drugs such as chloramphenicol or sulfonamides), viral infections (e.g., parvovirus B19, hepatitis viruses, Epstein-Barr virus), or underlying genetic predispositions (e.g., Fanconi anemia, dyskeratosis congenita). Diagnosis requires peripheral blood cytopenias in at least two lineages, bone marrow aspirate and biopsy demonstrating hypocellularity (<25% cellularity for age, or <50% with residual fat replacement), and exclusion of infiltrative, clonal, or autoimmune disorders (e.g., myelodysplastic syndromes, large granular lymphocyte leukemia, paroxysmal nocturnal hemoglobinuria). Risk stratification—based on severity (non-severe, severe, very severe)—guides therapeutic decisions.

Conservative management serves as supportive care and is essential across all disease severities. It includes rigorous infection prevention (hand hygiene, neutropenic precautions, avoidance of live vaccines), prompt empiric broad-spectrum antibiotics for febrile neutropenia (e.g., piperacillin-tazobactam ± vancomycin), antifungal prophylaxis (e.g., posaconazole or voriconazole) in high-risk patients, and transfusion support. Red blood cell transfusions are indicated for symptomatic anemia (e.g., Hb <7–8 g/dL or with fatigue, dyspnea, angina); however, chronic transfusion carries risks of iron overload, alloimmunization, and transfusion-transmitted infections. Platelet transfusions are reserved for active bleeding or platelet counts <10 × 10⁹/L (or <20 × 10⁹/L in febrile or septic patients). Iron chelation therapy (deferasirox or deferoxamine) is initiated after ≥20 units of RBCs or serum ferritin >1000 ng/mL to prevent end-organ damage. Growth factors (e.g., G-CSF) are not routinely recommended due to lack of survival benefit and theoretical risk of clonal evolution.

Pharmacologic therapy targets the underlying immune dysregulation. First-line immunosuppressive therapy (IST) for patients ineligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT)—particularly those over 40 years, lacking matched sibling donors, or with comorbidities—involves horse or rabbit antithymocyte globulin (ATG) combined with cyclosporine A (CsA). Horse ATG (equine-derived) demonstrates superior response rates (~60–70% at 6 months) compared to rabbit ATG (~30–40%), though both require careful monitoring for serum sickness, infusion reactions, and nephrotoxicity. CsA is titrated to maintain trough levels of 150–250 ng/mL and continued for ≥6 months post-response, then tapered slowly over 6–12 months to minimize relapse (occurring in ~30–40% of responders). Eltrombopag, a thrombopoietin receptor agonist, has revolutionized IST: when added to standard ATG/CsA, it significantly improves hematologic response rates (up to 90% at 6 months), accelerates trilineage recovery, and reduces relapse and clonal evolution. It is FDA- and NMPA-approved for refractory or first-line AA and is dosed at 50 mg daily, escalated to 150 mg based on tolerance and response. For refractory cases, second-line options include alemtuzumab, high-dose cyclophosphamide, or combination regimens; however, these carry higher toxicity and limited evidence.

Allogeneic hematopoietic stem cell transplantation remains the only curative modality and is the preferred first-line treatment for young patients (<40 years) with a human leukocyte antigen (HLA)-matched sibling donor. Outcomes are excellent: 5-year overall survival exceeds 90%, with rapid and durable engraftment. For patients lacking a matched sibling, matched unrelated donor (MUD) transplants have improved substantially with high-resolution HLA typing and post-transplant cyclophosphamide-based graft-versus-host disease (GVHD) prophylaxis, achieving 5-year survival of 75–85%. Haploidentical transplants are increasingly viable alternatives in experienced centers, particularly in China, where innovative platforms using T-cell depletion and optimized conditioning (e.g., fludarabine/cyclophosphamide/antithymocyte globulin) yield comparable outcomes to MUD. Transplant-related mortality, GVHD, and late effects (e.g., infertility, secondary malignancies) necessitate careful patient selection and long-term follow-up.

China offers distinct advantages in AA management. First, the National Clinical Research Center for Hematology (Tianjin) and leading institutions—including Peking University People’s Hospital, Shanghai Ruijin Hospital, and West China Hospital—have established standardized, evidence-based protocols aligned with international guidelines (EBMT, ASH, Chinese Society of Hematology). Second, China pioneered large-scale real-world studies validating eltrombopag in Asian populations and contributed pivotal data to global regulatory approvals. Third, cost-effectiveness is notable: NMPA-approved biosimilar ATG and domestically manufactured eltrombopag reduce treatment costs by 40–60% versus Western counterparts, improving accessibility. Fourth, China’s robust donor registries (China Marrow Donor Program, CMDP, with >3.5 million donors) and rapid HLA typing infrastructure enable timely donor identification. Fifth, integrated traditional Chinese medicine (TCM) adjuncts—such as Bu Zhong Yi Qi Tang or Shenmai injection—are used under strict clinical trial frameworks to ameliorate fatigue and improve quality of life, though they are never substituted for definitive therapy.

Recovery and long-term follow-up are critical. Patients achieving response must undergo lifelong surveillance: complete blood counts every 1–3 months for the first 2 years, then quarterly; annual bone marrow biopsies for the first 5 years to detect clonal evolution (e.g., monosomy 7, PNH clones, MDS). Vaccination status should be updated post-IST or transplant (avoiding live vaccines for ≥24 months post-IST or until immune reconstitution). Psychosocial support, nutritional counseling (iron- and folate-rich diet; avoidance of raw seafood/meats), and fertility preservation discussions (especially pre-transplant) are integral. Patients should avoid NSAIDs, aspirin, and herbal supplements with anticoagulant properties. Pregnancy requires multidisciplinary planning due to relapse risk and fetal complications. With modern therapies, 5-year survival exceeds 85% for severe AA treated appropriately—underscoring the importance of early referral to specialized hematology centers, timely risk stratification, and individualized integration of supportive, pharmacologic, and transplant strategies.